Evaluation of Sentinel Lymph Nodes in Head and Neck Squamous Cell Carcinoma
A Ph 3, Prospective, Open-Label, Multicenter Study of Lymphoseek®-Identified Sentinel Lymph Nodes (SLNs) Relative to the Path Status of Non SLN in an Elective Neck Dissection in Cutaneous Head and Neck and Intraoral Squamous Cell Carcinoma
Sponsor: Navidea Biopharmaceuticals
A PHASE3 clinical study on Head and Neck Squamous Cell Carcinoma (HNSCC), this trial is terminated or withdrawn. The trial is conducted by Navidea Biopharmaceuticals and has accumulated 12 data snapshots since 2009. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.
Status Flow
Change History
12 versions recorded-
Sep 2024 — Present [monthly]
Terminated PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE3
-
Jan 2023 — Jul 2024 [monthly]
Terminated PHASE3
-
Dec 2022 — Jan 2023 [monthly]
Terminated PHASE3
-
Dec 2021 — Dec 2022 [monthly]
Terminated PHASE3
▶ Show 7 earlier versions
-
Jan 2021 — Dec 2021 [monthly]
Terminated PHASE3
-
Nov 2020 — Jan 2021 [monthly]
Terminated PHASE3
-
Jun 2018 — Nov 2020 [monthly]
Terminated PHASE3
-
May 2018 — Jun 2018 [monthly]
Terminated PHASE3
-
Aug 2017 — May 2018 [monthly]
Terminated PHASE3
-
Feb 2017 — Aug 2017 [monthly]
Terminated PHASE3
-
Jan 2017 — Feb 2017 [monthly]
Terminated PHASE3
First recorded
May 2009
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Navidea Biopharmaceuticals
For direct contact, visit the study record on ClinicalTrials.gov .